Dear client, Key Highlights The following six topics will be discussed: CDK 4/6 Inhibition: The Next Big Thing in ER+ Breast Cancer Impresses at SABCS 2012 CDK inhibitors have been on key opinion leaders’ radars recently as very promising agents, and the results from the randomized Phase II trial combining PD 0332991 (Pfizer) with Femara® (letrozole,Novartis) did not disappoint. Long-Term Adjuvant Therapy Is Improving Outcomes in Breast Cancer and Is a Key Theme at SABCS 2012 Adjuvant therapy continues to improve outcomes in breast cancer. The HERA study showed that two years of Herceptin (trastuzumab, Roche) offered no additional benefit beyond what is achieved with one year of Herceptin, and the PHARE non-inferiority results showed that six months of therapy was inconclusive but potentially inferior to one year of Herceptin. So, one year of adjuvant Herceptin will remain the standard of care. In addition, The ATLAS data showed that 10 years of tamoxifen was superior to five years in ER+ patients. New MOAs in Multiple Myeloma Shine at ASH 2012 New mechanisms of action are showing promising activity in multiple myeloma. Awareness of the changing myeloma landscape will be critical for anyone thinking about initiating new pivotal Phase III trials in this disease. ARRY520 (Array), elotuzumab (BMS, Abbvie, Ono) and tabalumab (Eli Lilly) are highlighted. New Options Emerging for Elderly Acute Myeloid Leukemia (AML) Presentations of positive Phase II data in elderly AML patients at ASH 2012 suggest that two new targeted agents - quizartinib (AC220, Ambit Biosciences/Astellas) and volasertib (BI6727, Boehringer Ingelheim) - may be efficacious in this population and are poised to enter Phase III development within the next year. Not as BRIGHT as Hoped: Discordant Adverse Events in BRIGHT versus StiL Causes Stir at ASH 2012 Treanda (bendamustine, Teva, MundiPharma, Symbio), in combination with Rituxan (rituxmab, Roche), is vying for position in first-line Follicular Lymphoma, where R-CHOP is the standard of care. Data from the StiL study (presented at ASH 2009) suggested that R-Treanda is as effective as and less toxic than R-CHOP. The follow-up BRIGHT study was expected to produce more of the same, but the results, while positive, were disappointing with higher toxicity than expected. Pomalidomide Shatters Any Black Clouds at ASH 2012 Surrounding Its Future Use in Multiple Myeloma After a five-year dry-spell, the introduction of Kyprolis (carfilzomib, Onyx) this year and the impressive data for pomalidomide (Celgene) at ASH 2012 portend to a new era in multiple myeloma therapy. You are receiving this email because your subscription to CancerMPact ® entitles you to receive our complimentary oncology discussion piece, Oncology Conference Insight. We invite you to review the latest issue and download it directly from the Oncology Conference Insight website: http://oci.khapps.com This issue of Oncology Conference Insight highlights significant results presented at the 2012 San Antonio Breast Cancer Symposium (SABCS), which took place December 4 – 8 in San Antonio, Texas and the 2012 American Society of Hematology (ASH) Annual Meeting, which took place December 8 – 11, 2012, in Atlanta, Georgia. The discussion pieces available on this site summarize select presentations from key conferences for CancerMPact® subscribers. The discussions are intended to provide commercial organizations involved in the development and marketing of new cancer therapeutics with topical articles and features relating to oncology. Each edition will include news and comment about issues that may impact an organization's development and commercialization strategies, such as government policies and initiatives, pricing and reimbursement, and reports about the latest research on specific cancers by competitors. Additional information about forthcoming oncology meetings will also be included, together with features about Kantar Health’s Oncology products and services. Beyond the written pieces, at a custom offering level, Kantar Health’s Oncology Conference Insight service lets you define the scope of surveillance at any oncology conference. Then we report back to you, advising you of key takeaways, changes to standards of care, competitor activities and messaging, and new or emerging targets and compounds. The engagement delivers professional analysis and opinions on the implications. For more information on Oncology Conference Insight, send your contact information to: jocelyn.cappel@kantarhealth.com. Kantar Health Dr. Stephanie Hawthorne, Director Stephanie.Hawthorne@kantarhealth.com Bill Bagwell, General Manager Bill.Bagwell@kantarhealth.com